

Review the clinical development program

Get trained on RITUXAN HYCELA dosing & administration
Call 800-328-2154

RITUXAN HYCELA® (rituximab/hyaluronidase human) is indicated for the treatment of adult patients with:
Initiate treatment with RITUXAN HYCELA only after patients have received at least one full dose of RITUXAN®
RITUXAN HYCELA is not indicated for the treatment of non-malignant conditions
BOXED WARNINGS: SEVERE MUCOCUTANEOUS REACTIONS, HEPATITIS B VIRUS REACTIVATION and PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY
Severe Mucocutaneous Reactions
Hepatitis B Virus Reactivation
Progressive Multifocal Leukoencephalopathy (PML)
Hypersensitivity and Other Administration Reactions
Systemic Reactions
Local Cutaneous Reactions
Tumor Lysis Syndrome (TLS)
Infections
Cardiovascular Adverse Reactions
Renal Toxicity
Bowel Obstruction and Perforation
Immunization
Embryo-Fetal Toxicity
Please see the full Prescribing Information, including BOXED WARNINGS and Medication Guide, for additional Important Safety Information.
Attention Healthcare Provider: Provide Medication Guide to patient prior to RITUXAN HYCELA treatment.
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.